The confirmation of infection with human T-cell lymphotropic virus type I (HTLV-I) and type II (HTLV-II) currently involves multiple assays. These include Western blot (immunoblot) (WB) and/or radioimmunoprecipitation assay for detection of antibodies to HTLV-specific viral proteins and polymerase chain reaction and/or peptide-based enzyme immunoassays for differentiating between the two viruses. We undertook an evaluation of a modified WB assay that includes native HTLV-I viral proteins from MT-2 cells spiked with an HTLV-I transmembrane glycoprotein (recombinant p2le) and the HTLV-I-and HTLV-II-specific recombinant proteins MTA-1 and K55. The test panel consisted of well-characterized sera from U.S. blood donors, American Indians, intravenous drug users, and patients seen in sexually transmitted disease clinics. Of 158 HTLV-I/II-seropositive serum specimens tested, 156 (98.7%) were confirmed and typed as HTLV-I or HTLV-II. Of 82 HTLV-VII-seroindeterminate or -seronegative serum specimens, only 1 was classified as HTLV-U positive: the sample had weak gag p19 and strong gag p24 and env p2le reactivity and was radioimmunoprecipitation assay negative for env gp61/68 but polymerase chain reaction positive for HTLV-II. The specificity of the modified WB for confirming and typing serum samples was therefore 100%. We conclude that this WB assay is useful for confirming and typing HTLV infection and can help simplify HTLV-I/II testing algorithms.
HTLV-I/II-seropositive serum specimens tested, 156 (98.7%) were confirmed and typed as HTLV-I or HTLV-II. Of 82 HTLV-VII-seroindeterminate or -seronegative serum specimens, only 1 was classified as HTLV-U positive: the sample had weak gag p19 and strong gag p24 and env p2le reactivity and was radioimmunoprecipitation assay negative for env gp61/68 but polymerase chain reaction positive for HTLV-II. The specificity of the modified WB for confirming and typing serum samples was therefore 100%. We conclude that this WB assay is useful for confirming and typing HTLV infection and can help simplify HTLV-I/II testing algorithms.
Human T-cell lymphotropic virus type I (HTLV-I), the etiological agent of adult T-cell leukemia/lymphoma and of HTLV-I-associated myelopathy or tropical spastic paraparesis, is endemic in populations of Japan, the Caribbean, and parts of Africa (1) . HTLV-II is a virus closely related to HTLV-I, and antibodies to this virus cross-react with HTLV-I antigen. HTLV-II is prevalent in intravenous drug users (4, 10) and in some American Indian groups (7, 8) . Little is known, however, regarding HTLV-II and disease associations.
In the United States, HTLV-I/II screening of volunteer blood donors was instituted in late 1988. Of approximately 2,000 (15 in every 100,000 donors) HTLV-I/II-seropositive individuals identified each year, approximately half are infected with HTLV-I and half are infected with HTLV-II (2) . Counseling of these individuals is often limited by lack of knowledge as to whether they are infected with HTLV-I or HTLV-II.
Serologic testing for antibodies to HTLV-I/II involves a number of different techniques. Most (5) . A recombinant envelope protein which is recognized by HTLV-I-and HTLV-II-infected serum, env p2le (transmembrane glycoprotein), has been developed and used to spike HTLV-I viral lysates for WB, resulting in markedly improved sensitivity for confirming HTLV-I/II infection (14) . The specificity of envelope detection based on env p2le alone may, however, be suboptimal (6, 12) .
Because HTLV-I and HTLV-II are closely related, neither the EIA nor the WB or RIPA reliably differentiate between them, though the pattern of gag reactivity obtained by WB can suggest HTLV-I or HTLV-II infection (18) . To differentiate between the two viruses, polymerase chain reaction (PCR) has been used extensively, and more recently, specific HTLV-I and HTLV-II peptide-based EIAs have become available (13) . Another approach to confirm and differentiate infections is the incorporation of specific recombinant proteins unique to HTLV-I and HTLV-II in a modified WB (15, 16) . We report on the evaluation of a research WB with HTLV-I viral lysate, recombinant p2le, and additional recombinant proteins specific for detecting HTLV-I (MTA-1) (16) and HTLV-II (K55) (15) infection and describe its potential role in HTLV serologic testing.
MATERIALS AND METHODS
Serum specimens. A total of 240 serum specimens, repeatedly reactive by an HTLV-I ETA and additionally tested by e Adult T-cell leukemia/lymphoma or HTLV-I-associated myelopathy or tropical spastic paraparesis patients from Japan and the United States.
f HTLV-II-infected Guaymi Indians, Panama (11) .
WB and RIPA as previously described (17), were included in this evaluation. Of these specimens, 158 were classified as HTLV-I/II seropositive (reactivity to gag p24 and env gp46 or gp6l/68), 57 were classified as seroindeterminate (reactivity to gag p19 and/or p24 but no reactivity to env gp46 or gp6l/68), and 25 were classified as seronegative (no viral bands) ( Table 1) . Of the 158 seropositive specimens, 39 required RIPA to demonstrate HTLV-I/II env reactivity.
Peripheral blood mononuclear cells from 50 of the 158 HTLV-I/II-seropositive subjects were available for study by PCR as described elsewhere (9) . Of these, 14 subjects were found to be infected with HTLV-I and 36 were found to be infected with HTLV-II.
Of the remaining 108 HTLV-I/II-seropositive specimens, 89 were tested by synthetic peptide-based EIA to differentiate HTLV-I from HTLV-II infection (SynthEIA HTLV-I and SynthEIA HTLV-II [Olympus Corp., Lake Success, N.Y.], and/or Select-HTLV [Coulter/IAF Biochem International Inc., Montreal, Quebec, Canada]). Test results were interpreted according to the manufacturers' recommendations. Of these samples tested, 26 were HTLV-I positive, 52 were HTLV-II positive, and 11 were untypeable by synthetic peptide-based EIA. These tests have been shown to be 100% specific for differentiating HTLV-I and HTLV-II infections (18).
HTLV-I/H modified WB. The study WB strips were prepared by using HTLV-I viral lysate spiked with recombinant env p2le protein and specific recombinant proteins to HTLV-I (MTA-1) and HTLV-II (K55) as described previously (16 Md.). Results were tabulated on the basis of the presence or absence of specific HTLV bands on the WB (p19, p24, p2le, MTA-1, and K55; Fig. 1 
RESULTS
Of the 158 HTLV-I/Il-seropositive serum samples tested, 156 were confirmed and typed as HTLV-T or HTLV-II positive with the modified WB for a sensitivity of 98.7% (Table 2) . Of the 57 HTLV-I/II-seroindeterminate and 25 EIA-reactive but seronegative serum specimens studied, 1 (gag p24 reactive on standard testing) was classified as HTLV-II positive by the WB study strip ( Table 2 ). The sample showed weak p19 and strong p24, p2le, and K55 reactivity on the study WB but when tested by RIPA showed no evidence of antibody to env gp61/68. PCR amplification of peripheral blood mononuclear cells from this seroindeterminate subject confirmed HTLV-II infection. Excluding this truly infected sample, the specificity of the modified WB for confirming and typing HTLV-I and HTLV-II was therefore 100% (81 of 81). An additional seven serum samples (sixgag p24 reactive and one gag p19 and p24 reactive) reacted with gag p24 and env p2le on the WB study strip but not with MTA-1 or K55 (Table 2 ). Of these seven specimens, five were PCR negative (the other two were not tested by PCR). An additional five HTLV-seronegative and six gag p19-reactive samples (five of which were tested and found to be negative by PCR) also reacted with env p2le but not with gag p24, and seven other HTLV-seronegative samples showed gag reactivity with the modified WB ( Table 2) .
Two HTLV-I/II-seropositive samples showed reactivity to gag p19, p24, and env p2le but not to MTA-1 or K55 and were therefore classified as HTLV-I/II positive ( Table 2 ). The sensitivity of the modified WB for serological confirmation of HTLV-I/II infection was therefore 100% (158 of 158). However, seven HTLV-I/II-indeterminate serum specimens also showed gag p24 and env p2le reactivity ( (Fig. 1 ). All 36 PCR-classified HTLV-T1-positive specimens reacted to K55 recombinant protein; 1 of these samples cross-reacted with the HTLV-I recombinant protein MTA-1, but with weaker intensity than to K55 (Fig. 1) . Of 26 additional peptide-based EIA-typed HTLV-I-seropositive serum samples, 25 were reactive to MTA-1 and not to K55 and 1 was reactive to neither. Of 52 peptide-based EIA-typed HTLV-II-positive serum specimens, 51 reacted to K55; 1 of these cross-reacted with MTA-1 but at a lower intensity than with K55. One peptide-based EIA typed HTLV-II-positive serum sample did not react to K55 or to MTA-1. The study strip thus correctly distinguished between HTLV-1 and HTLV-II infection in 50 of 50 PCR-typed samples and 76 of 78 peptidebased EIA-typed samples. Of 11 HTLV-/IT-seropositive samples that were nontypeable by peptide-based EIA, 1 reacted with MTA-1 and not K55, 9 reacted with K55 and not MTA-1, and 1 reacted with both MTA-1 and K55, but with a much stronger reactivity to MTA-1 than to K55. Immunoreactivity with type-specific recombinant proteins on the study WB thus possibly allowed typing an additional 11 HTLV-T/TI-seropositive specimens. Of 47 HTLV I/II-indeterminate serum specimens from subjects who were also tested by PCR and found to be negative, 4 reacted with K55 and 43 did not demonstrate reactivity to either of the type-specific recombinant proteins. None of the four specimens that reacted with K55 demonstrated reactivity with other viral proteins (none were reactive to gag p24 and env p2le). These samples were retested in duplicate in separate laboratories, and reactivity to K55 could not be confirmed. creased the number of RIPAs needed to confirm envelope reactivity (6) . However, concerns regarding the specificity of recombinant p2le make it prudent not to rely on the presence of env p2le without additional proof of env reactivity in low-prevalence populations. This specifically applies to blood donor screening and other serodiagnostic usage in which individuals are notified regarding their infection status. The availability of synthetic peptide-based EIAs that differentiate between HTLV-I and HTLV-II, with reported sensitivities of over 80% (13) , has also been important. Although they require additional testing of a serum specimen, they are a great improvement over PCR, which has been the "gold standard" for typing infection but is not practical for large-scale studies or rapid diagnosis.
The modified WB assay, which combines env p21e and HTLV-I-and HTLV-II-specific recombinant proteins with an HTLV-I whole-virus lysate in a WB format, offers the possibility of confirming and differentiating HTLV-I and HTLV-II infection with a single test. In evaluating this assay, we examined both its ability to confirm and type HTLV infection and its ability to only confirm HTLV infection. The modified WB had a sensitivity of 98.8% and a specificity of 100% for confirming and classifying HTLV-I/II infection. Thus, samples that are confirmed and typed with this assay do not need additional testing. In our hands, the limited number of samples with reactivity to both the HTLV-I-and HTLV-II-specific recombinant proteins demonstrated a marked difference in the intensity of reaction to these two proteins, allowing us to properly classify them. It is possible that additional experience with this assay will reveal instances of dual reactivity that may not be that easy to classify and may need additional testing to differentiate HTLV-I from HTLV-II. Such results, when they occur, may represent infections with both HTLV-I and HTLV-II.
As expected on the basis of the reported sensitivity of p2le (6, 14) , the sensitivity of this modified WB was excellent (100%) for confirming HTLV-I/II infection. Therefore, serum samples not showing p2le reactivity with the modified WB can be resolved as HTLV-I/II indeterminate without a need for additional testing. However, as is the case with other assays using env p21e, relying on this protein alone for env reactivity resulted in false positivity. While this may be acceptable for anonymous testing and in the context of seroepidemiologic studies, it is desirable that individuals with env p2le and gag p24 but without additional evidence of env reactivity be further tested by RIPA or PCR prior to notification and counseling.
In conclusion, the modified WB strip appears to be useful. On the basis of its performance characteristics, we suggest that it be further evaluated with samples from other populations and geographic areas. Its use could benefit serosurveillance of HTLV; analysis of clinical specimens to aid in diagnosing HTLV-I; differentiation between HTLV-I and HTLV-II infection, which will be important to identify new disease associations; and confirmation of HTLV infection in conjunction with blood donor screening. Our evaluation of the strip addressed its role as a supplementary serologic test in conjunction with licensed HTLV-I whole-virus EIAs. Other issues have been raised regarding the sensitivity of the licensed screening assays for detection of HTLV-II (3). We studied serum samples screened with these assays and therefore are unable to address how the modified WB strip might perform with such HTLV-II-positive EIA-nonreactive samples.
